What Is Driving The Move In Corcept Therapeutics Stock?

CORTYTD+101.4%SPYYTD+8.2%XLVYTD+21.1%
Analyze CORT →

Today’s big story: Anthropic IPO: Priced For 2031, Or 2036?

Corcept Therapeutics (CORT) stock rose 101.2% from February 20 to November 17, 2026, while the S&P 500 returned 7.1% over the same dates. The shares peaked on August 25 and have fallen since. On April 1, early in that stretch, Corcept launched Lifyorli, its new drug for platinum-resistant ovarian cancer. So how big has Lifyorli become against everything else Corcept sells?

Image from Pixabay

Lifyorli Brings In About A Quarter Of Corcept’s Sales

Corcept’s third-quarter revenue was $340.5 million. On the November 3 call, management said Lifyorli brought in $91.4 million of it. That makes a drug Corcept did not sell before April about 27% of its sales.

The new drug arrived as overall growth picked up. Corcept’s third-quarter revenue grew 64% from a year earlier. In the first quarter, before Lifyorli went on sale, it grew 4.9%. The shares made their biggest one-day gain of the stretch on July 30, rising 27.3%. That was the session after Corcept reported its second quarter, the first full quarter with Lifyorli on sale. The shares then reached their highest close of the stretch, $123.57, on August 25. They have since lost ground and closed at $70.07 on November 17.

How Has Corcept’s Profit Changed Since The Launch?

Corcept has gone from an operating loss to a growing operating profit over 2026. The company recorded a $49.6 million operating loss in the first quarter. It then earned $41.3 million in operating income in the second. Third-quarter operating income reached $115 million, an operating margin of 33.7%. In the same quarter of 2025, the operating margin was 4.9%.

The twelve months to September 30, 2026 still include the first-quarter loss. The operating margin over that period was 11.5%. For the twelve months to September 2024, it was 22.8%. A year later it was 8.8%. So the margin has risen over the latest year but remains below its 2024 level.

What Has Not Changed At Corcept?

Most of Corcept’s sales still come from Korlym and its authorized generic. Corcept sells both for Cushing’s syndrome. Together they brought in $249.1 million in the third quarter. Corcept also still has almost no debt. It owed $8.99 million on September 30, 2026, up from $6.36 million a year before.

Lifyorli is the brand name for relacorilant. The FDA is still reviewing relacorilant as a treatment for Cushing’s syndrome. Corcept resubmitted its application for that use on June 17, 2026. Management said on the November 3 call that it expects the FDA’s decision by December 17. That decision is the one to watch.

Few holders in February could have known how fast a new drug would sell. No one yet knows how the FDA review due in December will turn out. News like that is hard to predict one stock at a time.

Stop Guessing. Start Positioning.

No one can predict surprises like this one. The Trefis High Quality (HQ) Portfolio doesn’t try: it holds 30 quality stocks in equal weight, so no single surprise decides your result. Come see how it works.

See How HQ Works

Spot an error or want more like this? Tell us in 10 seconds.